Latest News on XERS

Financial News Based On Company


Advertisement
Advertisement

XERS: RECORLEV’s acceleration and broad-based product growth underpin a greater-than-$1B 2030 outlook

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4664538:0-xers-recorlev-s-acceleration-and-broad-based-product-growth-underpin-a-greater-than-1b-2030-outlook/
Xeris Biopharma Holdings (XERS) has raised its FY2026 revenue guidance to $395M-$405M and projects its 2030 outlook to exceed $1B, driven by growth across all three marketed products. The company also plans to initiate its XP-8121 Phase III trial by year-end 2026, with top-line data anticipated by year-end 2028. This positive outlook is based on insights from the Jefferies Global Healthcare Conference.

Top 3 Health Care Stocks That May Collapse This Month

https://www.benzinga.com/trading-ideas/short-ideas/26/11/63289310/top-3-health-care-stocks-that-may-collapse-this-month-2
This article identifies three healthcare stocks—Surgery Partners Inc (SGRY), Mentari Therapeutics, Inc. (MTRI), and Xeris Biopharma Holdings Inc (XERS)—that may be overbought according to their Relative Strength Index (RSI) values, signaling a potential short-term pullback. Each company has seen significant recent stock gains and strong operational or analyst reports, yet their high RSI indicates they could be flashing a warning to momentum-focused investors.

Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?

https://stocktwits.com/news-articles/markets/equity/why-did-mrna-xers-vir-stocks-surge-to-52-week-highs-last-week/cNGAUjuR9ec
Moderna (MRNA), Xeris Biopharma (XERS), and Vir Biotechnology (VIR) shares all surged to 52-week highs on Friday. MRNA saw a more than 5% increase after strong Q3 results led to price target hikes from analysts. XERS rocketed over 16% due to Wall Street optimism and an increased 2030 revenue outlook, while VIR rallied nearly 11% amid price target increases and anticipation of expanded Phase 2 Solstice trial data.

Why Xeris Biopharma Holdings (XERS) Is Up 25.0% And What's Next

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-holdings-xers-is-up-250-and-whats-next
Xeris Biopharma Holdings (XERS) saw a 25.0% increase following a strong third quarter in 2026, reporting US$107.23 million in revenue and a net income of US$11.29 million. Despite a profitable quarter, the company still has a nine-month net loss of US$17.58 million, highlighting execution risk. The company's investment narrative hinges on its commercial therapies and pipeline advancements without balance sheet strain, with analyst forecasts projecting significant revenue and earnings growth by 2029.

Xeris Pharma stock climbs on Q3 beat (XERS:NASDAQ)

https://seekingalpha.com/news/4667017-xeris-pharma-stock-climbs-q3-beat
Xeris Pharmaceuticals (XERS) saw its stock approach a new 52-week high after reporting stronger-than-expected Q3 2026 financial results. The company also raised its revenue outlook, now projecting over $1 billion in revenue by the end of the decade. Xeris recorded $107.2 million in revenue for the quarter.
Advertisement

Xeris Biopharma stock hits 52-week high at 12.53 USD

https://www.investing.com/news/company-news/xeris-biopharma-stock-hits-52week-high-at-1253-usd-93CH-5004808
Xeris Biopharma Holdings, Inc. stock recently achieved a 52-week high of $12.53 and is currently trading at $12.84, reflecting significant growth over the past six months and year. Despite this strong market performance and an impressive gross profit margin, InvestingPro analysis suggests the stock might be overvalued. The company also reported Q2 2026 earnings, surpassing revenue estimates but missing profit expectations due to a non-cash GAAP charge, while Oppenheimer reiterated an Outperform rating based on a promising new drug candidate.

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.biospace.com/press-releases/xeris-biopharma-reports-third-quarter-2026-financial-results-and-business-highlights
Xeris Biopharma Holdings, Inc. announced strong financial results for the third quarter of 2026, with total revenue increasing 44% year-over-year to $107.2 million, primarily driven by a 93% rise in Recorlev net revenue. The company raised its full-year 2026 total revenue guidance to $395-$405 million and its 2030 outlook to over $1 billion. Key business highlights include the full retirement of 2028 Convertible Notes, advancement of the XP-8121 program, and the granting of new patents for XP-8121 and Keveyis.

Xeris Biopharma Holdings Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62919298/xeris-biopharma-holdings-q3-2026-earnings-call-transcript
Xeris Biopharma Holdings reported a 44% year-over-year increase in total revenue for Q3 2026, driven by strong performances from Recorlev, Gvoke, and Keveyis. The company raised its full-year revenue guidance to $395-$405 million and projects over $1 billion in revenue by 2030, up from a previous estimate of $750 million. Recorlev’s revenue surged by 93% due to expanded commercial efforts, while Gvoke and Keveyis also showed growth, and the late-stage XP8121 program is progressing towards a pivotal Phase 3 study by year-end.

Xeris Biopharma raises sales outlook after US$107.2M quarter

https://mugglehead.com/xeris-biopharma-third-quarter-sales-guidance-debt-thyroid-study/
Xeris Biopharma reported a strong third quarter with sales up 44 percent to US$107.2 million and net income climbing to US$11.3 million. The company raised its full-year 2026 revenue forecast to US$395 million to US$405 million, driven by strong demand for its drug Recorlev. Xeris also remains on track to initiate a pivotal Phase 3 thyroid-treatment study by the end of 2026 and expects over US$1 billion in total revenue by 2030.

Xeris Biopharma Beats As Recorlev Nearly Doubles, Revenue Growth Reaccelerates And The 2030 Target Jumps To $1 Billion

https://finviz.com/news/417295/xeris-biopharma-beats-as-recorlev-nearly-doubles-revenue-growth-reaccelerates-and-the-2030-target-jumps-to-1-billion
Xeris Biopharma exceeded Q3 expectations, with earnings per share at $0.06 against a $0.02 consensus and revenue of $107.23 million beating estimates. The company raised its full-year 2026 revenue guidance to $395-$405 million and increased its 2030 total revenue outlook to over $1 billion, driven significantly by the strong performance of Recorlev. Despite some concerns about rising SG&A costs and Recorlev's access hurdles, the company's Q3 results demonstrated significant operational acceleration and improved profitability.
Advertisement

Xeris Biopharma COO Kevin McCulloch sells $153,487 in shares

https://www.investing.com/news/insider-trading-news/xeris-biopharma-coo-kevin-mcculloch-sells-153487-in-shares-93CH-5002427
Kevin McCulloch, COO of Xeris Biopharma Holdings (NASDAQ:XERS), sold 15,000 shares for $153,487 on November 2, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred after the stock surged 68% over six months, nearing its 52-week high, with InvestingPro analysis suggesting it's overvalued. McCulloch still directly holds over 1.58 million shares.

Xeris Biopharma Holdings, Inc. Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/XERS/form-3-xeris-biopharma-holdings-inc-initial-statement-of-beneficial-o-aac808ecdd3e.html
This article details an initial statement of beneficial ownership (Form 3) filed by Menassie Taddese for Xeris Biopharma Holdings, Inc. The filing indicates that Mr. Taddese is a Director but beneficially owns no securities. The document was filed with the SEC on November 4, 2026, and relates to an event on November 2, 2026.

Xeris adds longtime biotech exec to its board

https://www.chicagobusiness.com/health-care/ccb-taddese-xeris-board-20261103/
Xeris Biopharma has announced the addition of Menassie Taddese, a longtime biotech executive, to its board of directors. The article mentions this development as a key update for the company.

What Xeris Biopharma Doubters Overlooked

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/what-xeris-biopharma-doubters-overlooked
Xeris Biopharma's stock has risen 38.4% year-to-date, fueled by progress on its XP-8121 candidate and existing endocrine portfolio. While Q1 2026 showed a profit, Q2 revealed a significant loss despite increased revenue, highlighting the importance of profitability tracking. Investors today are betting on XP-8121 to justify the company's increased spending and higher valuation, despite risks related to payer pressure and product execution.

Form 144 XERIS BIOPHARMA HOLDINGS For: 3 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-xeris-biopharma-holdings-for-3-november-93CH-4924040
Investing.com reported a Form 144 filing for Xeris Biopharma Holdings, dated November 3rd. The article briefly mentions the company's stock symbol, XERS, which saw a 2.85% increase. No further details about the Form 144 filing itself are provided.
Advertisement

Officer Beth Hecht proposes selling 75,000 Xeris Biopharma (XERS) shares.

https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-55e2477978a4.html
Beth Hecht, an officer at Xeris Biopharma Holdings, Inc. (XERS), has filed a Form 144 proposing the sale of 75,000 common shares with an aggregate market value of $803,250.00. These shares were acquired through the vesting of restricted stock units between January 3 and January 31, 2025. The filing also details three earlier 10b5-1 sales made by Hecht in August, September, and October of 2026.

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

https://www.biospace.com/press-releases/xeris-biopharma-welcomes-menassie-m-taddese-to-board-of-directors
Xeris Biopharma Holdings, Inc. announced the appointment of Menassie M. Taddese to its Board of Directors, effective November 2, 2026. Taddese, an experienced biopharmaceutical executive with nearly 30 years of global leadership, will also serve on the Board’s Audit Committee. His expertise in commercial operations, corporate finance, and public company governance is expected to provide valuable guidance as Xeris continues to expand its commercial portfolio and advance its clinical pipeline.

Form 8K Xeris Biopharma Holdings, Inc For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-xeris-biopharma-holdings-inc-for-2-november-93CH-4922085
This article announces that Xeris Biopharma Holdings, Inc. filed a Form 8K on November 2, 2026. The filing is available through Investing.com, a financial news platform that also provides market data and analysis. The brief article provides no further details on the content of the 8K filing.

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

https://www.businesswire.com/news/home/20261102898192/en/Xeris-Biopharma-Welcomes-Menassie-M.-Taddese-to-Board-of-Directors
Xeris Biopharma Holdings, Inc. announced the appointment of Menassie M. Taddese to its Board of Directors, effective today, where he will also serve on the Audit Committee. Taddese brings nearly 30 years of global leadership experience in biopharmaceuticals, including commercial operations, corporate finance, and governance, having previously served as President, Emerging Markets at Viatris and holding various roles at Pfizer. His expertise is expected to provide valuable perspective as Xeris continues to expand its commercial portfolio and advance its clinical pipeline.

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

https://www.financialcontent.com/article/bizwire-2026-11-2-xeris-biopharma-welcomes-menassie-m-taddese-to-board-of-directors
Xeris Biopharma Holdings, Inc. announced the appointment of Menassie M. Taddese to its Board of Directors, effective today, where he will also serve on the Audit Committee. Taddese brings nearly 30 years of global leadership experience in biopharmaceuticals, including commercial operations, corporate finance, and governance, most recently as President, Emerging Markets at Viatris. This appointment aims to leverage his expertise to support Xeris's strategic execution and value creation.
Advertisement

Xeris Biopharma Holdings, Inc. (XERS) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/XERS/seasonality/
This article provides a seasonal returns chart for Xeris Biopharma Holdings, Inc. (XERS), displaying the average monthly price return from 2018 to 2026. It includes current stock information, showing a slight decrease at market close on October 30th but a small increase after hours. The page also features navigation links to various financial data sections for XERS.

XERS Stock Price, Quote & News

https://www.syfe.com/stocks/us/xers
This article provides an overview of Xeris Biopharma Holdings, Inc. (XERS) stock, including its current trading price, market capitalization, and key statistics. It also details the company's biopharmaceutical products like Gvoke, Keveyis, and Recorlev, and lists recent market chatter and insider transaction news. The article concludes with an FAQ section addressing common questions about XERS stock.

Vanguard reports a Xeris Biopharma (XERS) stake with voting power over 1.38M shares.

https://www.stocktitan.net/sec-filings/XERS/schedule-13g-a-xeris-biopharma-holdings-inc-amended-passive-investmen-9a8915cf0c50.html
Vanguard Capital Management reported an amended 4.98% beneficial ownership stake in Xeris Biopharma Holdings, Inc. (XERS), totaling 9,086,791 common shares as of September 30, 2026. The filing indicates Vanguard has sole voting power over 1,376,435 shares and sole dispositive power over all 9,086,791 shares, with no shared voting or dispositive power reported. This disclosure was made via a Schedule 13G/A SEC filing.

Xeris Biopharma stock: Xeris schedules November 5 results for Xeris Biopharma stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/xeris-biopharma-stock-xeris-schedules-november-5-results-for-xeris-biopharma-stock/70401596
Xeris Biopharma Holdings (XERS) is scheduled to report its third-quarter 2026 results on November 5, 2026, with revenue guidance of USD 385 million to USD 390 million for the full year. The company previously reported second-quarter revenue of USD 92.10 million, a 29% year-over-year increase, and has a market capitalization of USD 1.9 billion as of October 23, 2026. The report and a conference call will take place before the U.S. market opens, providing a clear benchmark for the company's performance against its raised guidance.

Xeris Biopharma Holdings, Inc. Estimates – NASDAQ:XERS

https://www.tradingview.com/symbols/NASDAQ-XERS/financials-estimates/
The article provides an overview of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) financials and analyst estimates available on TradingView. It covers reported financial data and estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.
Advertisement

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

https://www.biospace.com/press-releases/xeris-biopharma-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026
Xeris Biopharma Holdings, Inc. announced it will release its third-quarter 2026 financial results and business highlights on Thursday, November 5, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss these results and provide business updates. Interested parties can pre-register for the call or access details on the investor relations website.

Xeris presents endocrine data for Xeris Biopharma stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/xeris-presents-endocrine-data-for-xeris-biopharma-stock/70373293
Xeris Biopharma announced presentations at three endocrine-related scientific meetings on October 15, 2026, covering its products Gvoke, Recorlev, and the investigational XP-8121 program. Barclays subsequently raised its target for Xeris stock from $12.00 to $14.00 on October 6, 2026, maintaining an Overweight rating. The company's third-quarter results are anticipated on November 5, 2026, with a presentation at the American Thyroid Association meeting scheduled for November 6, 2026.

Xeris Biopharma stock hits 52-week high at 11.38 USD By Investing.com

https://za.investing.com/news/stock-market-news/xeris-biopharma-stock-hits-52week-high-at-1138-usd-93CH-4512297
Xeris Biopharma Holdings, Inc. stock reached a new 52-week high of $11.38, reflecting a 62% surge over the past six months and a 19.97% increase over the past year. Despite trading above its Fair Value according to InvestingPro, the company boasts impressive gross profit margins of 87% and 36% revenue growth. Recent financial results show a revenue increase to $92.1 million, though the company reported a loss of $0.18 per share due to a one-time non-cash GAAP charge.

Xeris Biopharma stock hits 52-week high at 11.38 USD

https://www.investing.com/news/company-news/xeris-biopharma-stock-hits-52week-high-at-1138-usd-93CH-4958072
Xeris Biopharma Holdings, Inc. (XERS) stock has reached a 52-week high of $11.38, reflecting a 62% surge over the past six months and a 19.97% increase over the past year. Despite trading above its Fair Value according to InvestingPro analysis, the company boasts impressive gross profit margins of 87% and 36% revenue growth. Recent financial results showed a revenue increase to $92.1 million in Q2 2026, though the company reported a loss per share attributed to a one-time non-cash charge.

Xeris Biopharma stock hits 52-week high at 11.38 USD By Investing.com

https://uk.investing.com/news/stock-market-news/xeris-biopharma-stock-hits-52week-high-at-1138-usd-93CH-4918139
Xeris Biopharma Holdings, Inc. stock recently reached a 52-week high of $11.38, reflecting a 62% surge over the past six months and a 19.97% increase over the past year. Despite trading above its Fair Value, the company maintains impressive gross profit margins of 87% and 36% revenue growth, driven by strong demand for RECORLEV and Gvoke, though it reported a Q2 2026 loss of $0.18 per share. Oppenheimer reiterated an Outperform rating with an $18.00 price target, citing potential for its XP-8121 candidate for hypothyroidism.
Advertisement

Form 144 XERIS BIOPHARMA HOLDINGS For: 18 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-xeris-biopharma-holdings-for-18-october-93CH-5639288
This article announces the filing of Form 144 for Xeris Biopharma Holdings (NASDAQ:XERS) on October 18, published by Investing.com. Form 144 indicates an intent to sell restricted securities. The article provides only this notification without further details about the transaction.

Form 144 XERIS BIOPHARMA HOLDINGS For: 18 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-xeris-biopharma-holdings-for-18-october-93CH-4887209
The article reports on a Form 144 filing for Xeris Biopharma Holdings, specifically referencing activity on October 18th. It is a brief announcement from Investing.com and provides no further details about the filing itself. The article also includes various market data and other news headlines that are unrelated to the main subject.

Xeris files KEVEYIS suits. Barclays lifts target for Xeris Biopharma Holdings stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/xeris-files-keveyis-suits-barclays-lifts-target-for-xeris-biopharma-holdings-stock/70353577
Xeris Biopharma Holdings has filed two patent infringement lawsuits related to its KEVEYIS product, citing U.S. Patent No. 12,758,502. This legal action enhances its intellectual property defense alongside commercial growth and upcoming clinical data. Barclays recently raised its price target for Xeris stock from $12.00 to $14.00, maintaining an Overweight rating, reflecting confidence in the company's growth drivers.

Xeris Biopharma presents data on endocrine therapies at fall meetings

https://www.investing.com/news/company-news/xeris-biopharma-presents-data-on-endocrine-therapies-at-fall-meetings-93CH-4951531
Xeris Biopharma Holdings, Inc. announced presentations of clinical and scientific data from its commercial portfolio and development pipeline at three scientific meetings. The presentations cover Gvoke for severe hypoglycemia, Recorlev for Cushing’s Syndrome, and the investigational XP-8121 program for hypothyroidism. Data presented include insights into healthcare provider awareness of diabetes treatment guidelines and a case study demonstrating cortisol normalization with levoketoconazole.

Xeris files KEVEYIS patent suits and Xeris Biopharma Holdings stock trades at EUR 8.60

https://www.ad-hoc-news.de/boerse/news/nebenwerte/xeris-files-keveyis-patent-suits-and-xeris-biopharma-holdings-stock-trades/70329282
Xeris Biopharma Holdings has filed two patent infringement lawsuits regarding generic versions of its drug KEVEYIS, seeking injunctions and damages. This legal action follows a strong second quarter in 2026, where the company reported significant revenue growth and raised its full-year guidance. As of October 15, 2026, Xeris Biopharma Holdings stock is trading at EUR 8.60 with a market capitalization of USD 1.8 billion.
Advertisement

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

https://www.biospace.com/press-releases/xeris-biopharma-reinforces-leadership-in-endocrinology-with-data-disclosures-spanning-commercial-portfolio-and-pipeline-at-multiple-scientific-meetings
Xeris Biopharma announced clinical and scientific data presentations from its commercial portfolio and development pipeline at three fall scientific meetings, highlighting its leadership in endocrinology. The presentations covered Gvoke for severe hypoglycemia, Recorlev for Cushing's Syndrome, and the investigational XP-8121 program for hypothyroidism. These disclosures emphasize Xeris's commitment to advancing patient care with both established therapies and emerging treatment approaches.

Xeris Biopharma CFO Steven Pieper sells $47,036 in stock

https://www.investing.com/news/insider-trading-news/xeris-biopharma-cfo-steven-pieper-sells-47036-in-stock-93CH-4945814
Xeris Biopharma CFO Steven Pieper sold 5,000 shares of the company's common stock for a total of $47,036 on October 1, 2026, under a Rule 10b5-1 trading plan. Despite a 75% gain in stock value over the past six months, InvestingPro's analysis suggests the stock might be overvalued. The sale occurred after the company reported strong Q2 2026 revenue, though it missed profit projections, and Oppenheimer reiterated an Outperform rating with an $18 price target.

Form 4 Xeris Biopharma Holdings, Inc: Steven Pieper (Officer) For: 1 October

https://ng.investing.com/news/stock-market-news/form-4-xeris-biopharma-holdings-inc-steven-pieper-officer-for-1-october-93CH-2733091
This article reports that Steven Pieper, an Officer at Xeris Biopharma Holdings, Inc., filed a Form 4 on October 1st. Form 4 filings are used to declare transactions in company stock by corporate insiders. The article does not provide specific details about the nature of the transaction.

Xeris Biopharma COO McCulloch sells $141,120 in shares

https://www.investing.com/news/insider-trading-news/xeris-biopharma-coo-mcculloch-sells-141120-in-shares-93CH-4945813
Kevin McCulloch, COO of Xeris Biopharma Holdings, sold 15,000 shares of the company's common stock for $141,120 on October 1, 2026, pursuant to a pre-arranged trading plan. Despite the sale, McCulloch retains a significant direct and indirect ownership in the company. This transaction follows recent financial results where Xeris Biopharma exceeded revenue estimates but reported a loss per share, and Oppenheimer reiterated an Outperform rating on the company.

Form 4 Xeris Biopharma Holdings, Inc: Beth Hecht (Officer) For: 1 October

https://in.investing.com/news/stock-market-news/form-4-xeris-biopharma-holdings-inc-beth-hecht-officer-for-1-october-93CH-5629890
This article reports on a Form 4 filing for Xeris Biopharma Holdings, Inc., indicating that Beth Hecht, an officer, made a transaction on October 1st. The filing details are specific to the individual officer and the date of the transaction. No further details about the nature of the transaction are provided in the snippet.
Advertisement

Xeris Biopharma CLO Beth Hecht sells $156,792 in XERS shares

https://www.investing.com/news/insider-trading-news/xeris-biopharma-clo-beth-hecht-sells-156792-in-xers-shares-93CH-4945793
Beth Hecht, CLO of Xeris Biopharma, sold 16,666 shares of XERS stock for approximately $156,792 on October 1, 2026, under a Rule 10b5-1 trading plan. Following the sale, she directly holds 1,111,130 shares. The company recently reported a 29% revenue increase in Q2 2026, surpassing Wall Street expectations, and Oppenheimer reiterated an Outperform rating with an $18 price target.

Barclays raised Xeris Biopharma stock target to USD 14.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barclays-raised-xeris-biopharma-stock-target-to-usd-14-00/70264988
Barclays has increased its price target for Xeris Biopharma (XERS) stock from USD 12.00 to USD 14.00, maintaining an Overweight rating. This update follows Xeris Biopharma's Q2 2026 results, where net product revenue grew 34% year-over-year, and Recorlev revenue surged 81%. The stock's performance and future valuation are closely tied to the execution of its commercial portfolio and XP-8121 program.

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

https://www.benzinga.com/news/26/10/62184121/full-transcript-xeris-biopharma-holdings-q2-2026-earnings-call
Xeris Biopharma Holdings reported a record-breaking Q2 2026 with $92 million in total revenue, driven by 34% year-over-year growth in net product revenue, primarily from Recorlev's 81% growth. The company strengthened its IP, retired convertible notes saving $3 million in annual interest, and raised its full-year 2026 revenue guidance to $385-$390 million. Significant progress was also made on the XP8121 pipeline with a Phase 3 start expected by year-end, positioning the company for continued growth.

An officer plans a $159K share sale at Xeris Biopharma (XERS).

https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-cdbed3da4b98.html
Xeris Biopharma officer Beth Hecht plans to sell 16,666 common shares, valued at approximately $159,326.96, with an approximate sale date of October 1, 2026. This intended sale follows two previous 10b5-1 sales of 16,666 shares each in August and September 2026. The transaction is being handled through Morgan Stanley Smith Barney LLC.

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

https://finance.yahoo.com/healthcare/articles/lundbeck-approaches-xeris-biopharma-over-201736994.html
Danish pharmaceutical company H Lundbeck is reportedly exploring a potential takeover of Chicago-based Xeris Pharmaceuticals Inc, a commercial-stage drugmaker. While discussions are preliminary and Xeris stated it is "not for sale," Lundbeck is working with financial advisers to consider the acquisition. The move would expand Lundbeck's presence into rare endocrine disorders, leveraging Xeris's $1.8 billion market valuation against Lundbeck's larger $6.6 billion market cap.
Advertisement

XERS5927663 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-XERS5927663/profile/
This article provides a detailed profile of the XERS5927663 bond issued by Xeris Biopharma Holdings, Inc. It outlines key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes information on the bond's 8.0% semi-annual fixed-rate coupon payments and redemption details.

Lundbeck is weighing a bid for Xeris Biopharma, per people familiar

https://www.briefs.co/news/lundbeck-is-weighing-a-bid-for-xeris-biopharma-per-people-fa/
Danish drugmaker H Lundbeck A/S is reportedly considering an acquisition of Chicago-based Xeris Biopharma, known for its injectable treatments for endocrine and rare conditions. Lundbeck has engaged advisers to assess a potential deal, though Xeris has stated it is not for sale. The news sent Xeris shares to a 2019 high, while Lundbeck's stock dipped slightly.

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

https://www.investing.com/news/stock-market-news/lundbeck-approaches-xeris-biopharma-over-potential-takeover-bloomberg-reports-4923390
Danish pharmaceutical company H Lundbeck has reportedly approached Chicago-based Xeris Pharmaceuticals Inc. regarding a potential takeover. While Lundbeck is working with financial advisers to explore an acquisition, discussions are preliminary and may not lead to a formal transaction. Xeris, which focuses on endocrine and rare diseases, has a market valuation of about $1.8 billion, and a spokeswoman for the company stated it is "not for sale."

Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo Finance

https://ca.finance.yahoo.com/quote/XERS/
This article provides a detailed financial overview of Xeris Biopharma Holdings, Inc. (XERS), including its stock price, historical data, key financial metrics, and analyst insights. It covers the company's product offerings, pipeline, and recent performance compared to the S&P 500. The report also includes valuation measures, profitability data, and balance sheet highlights for investors.

Xeris Biopharma stock hits 52-week high at 10.08 USD By Investing.com

https://ng.investing.com/news/stock-market-news/xeris-biopharma-stock-hits-52week-high-at-1008-usd-93CH-2714442
Xeris Biopharma's stock reached a new 52-week high of $10.08 USD, reflecting an 82% surge over six months and a 25% year-to-date gain, driven by strong gross profit margins and revenue growth. Despite this, InvestingPro analysis suggests the stock may be overvalued, with RSI indicating overbought conditions. The company recently reported strong Q2 2026 revenue of $92.1 million, exceeding estimates, and Oppenheimer reiterated an Outperform rating due to the potential of its XP-8121 drug candidate.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement